<?xml version="1.0" encoding="UTF-8"?>
<list list-type="bullet" id="list18-0020731420946590">
 <list-item>
  <p>As far as prevention is concerned, the rVSV-ZEBOV vaccine was successfully used in the Democratic Republic of the Congo 2018–2019 outbreak. Surveillance, contact tracing, and quarantine are effective. A multidrug therapy is being tested. Supportive treatment is moderately effective.
   <sup>
    <xref rid="bibr74-0020731420946590" ref-type="bibr">74</xref>
   </sup>
  </p>
 </list-item>
 <list-item>
  <p>R0 has been 1 to 1.3
   <sup>
    <xref rid="bibr75-0020731420946590" ref-type="bibr">75</xref>
   </sup> and even 1.5.
   <sup>
    <xref rid="bibr76-0020731420946590" ref-type="bibr">76</xref>,
    <xref rid="bibr77-0020731420946590" ref-type="bibr">77</xref>
   </sup>
  </p>
 </list-item>
 <list-item>
  <p>With regard to incidence, 29,000 cases occurred in Sierra Leone, Liberia, and Guinea during the 2014–2016 epidemic. Of these, 27% of infections were asymptomatic.
   <sup>
    <xref rid="bibr78-0020731420946590" ref-type="bibr">78</xref>
   </sup>
  </p>
 </list-item>
 <list-item>
  <p>CFR is 50% (25%–90%).</p>
 </list-item>
 <list-item>
  <p>There were 11,500 deaths during the Sierra Leone, Liberia, and Guinea epidemic in 2014–2016.</p>
 </list-item>
 <list-item>
  <p>The greatest risk of secondary attack is in nursing care and health care services in general.</p>
 </list-item>
 <list-item>
  <p>Only a few imported cases occurred in Europe (primarily health professionals contaminated in Africa and treated in Europe).</p>
 </list-item>
</list>
